# A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

> **NCT04542057** · PHASE3 · COMPLETED · sponsor: **Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA** · enrollment: 790 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Ensifentrine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04542057
- **Lead sponsor:** Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-22
- **Primary completion:** 2022-05-03
- **Final completion:** 2022-07-06
- **Target enrollment:** 790 (ACTUAL)
- **Last updated:** 2023-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04542057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04542057, "A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04542057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*